Trials / Completed
CompletedNCT01270256
NasoNeb Delivery of an Intranasal Steroid
Evaluation of NasoNeb™ Delivery of an Intranasal Steroid in the Treatment of Perennial Allergic Rhinitis
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- University of Chicago · Academic / Other
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to see if a nasal steroid drug delivered to the nose with the NasoNeb™ inhaler improves the symptoms of people with perennial allergic rhinitis (year round allergy symptoms).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Budesonide | Pulmicort Respules at a dose of 0.25 mg. delivered intranasally via NasoNeb nebulizer once daily |
| DRUG | Placebo | Placebo delivered intranasally via NasoNeb nebulizer once daily |
Timeline
- Start date
- 2011-01-01
- Primary completion
- 2012-07-01
- Completion
- 2012-08-01
- First posted
- 2011-01-05
- Last updated
- 2014-07-25
- Results posted
- 2014-07-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01270256. Inclusion in this directory is not an endorsement.